Breaking News Instant updates and real-time market news.

MNLO

Menlo Therapeutics

$35.22

-1 (-2.76%)

10:27
04/09/18
04/09
10:27
04/09/18
10:27

Menlo Therapeutics sinks after Phase 2 trial of serlopitant misses endpoints

Shares of Menlo Therapeutics are falling after the company announced its Phase 2 clinical trial of serlopitant did not meet its primary or key secondary endpoints. MTI-103 RESULTS: On Sunday, Menlo Therapeutics, which went public on January 25, announced results from MTI-103, the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis. The study did not meet its primary or key secondary efficacy endpoints, and the trial showed no statistically significant difference between patients treated with serlopitant and patients treated with placebo. The ATOMIK, MTI-103 study, was a multi-center, randomized, placebo-controlled Phase 2 clinical trial conducted at 52 U.S. sites to assess the efficacy, safety and tolerability of serlopitant. The primary efficacy analysis compared the difference between serlopitant and placebo in the mean change in worst-itch numeric rating scale from baseline to week 6. A key secondary endpoint was a responder-rate analysis of a 4-point WI-NRS improvement at week 6. EXECUTIVE COMMENTARY: "While we are disappointed that the results in this Phase 2 trial of pruritus associated with atopic dermatitis did not reach statistical significance and did not show the same magnitude of treatment effect as in our prior pruritus studies, we do see in the results a pattern that shows numerical improvement in each serlopitant treatment group above the placebo group at every timepoint. This is our third pruritus study of serlopitant. Reduction of pruritus has been demonstrated in two prior Phase 2 studies, one trial in patients with chronic pruritus and one trial in patients with prurigo nodularis," said Chief Executive Officer Steve Basta. "We are initiating Phase 3 studies in prurigo nodularis this quarter, and we are looking forward to the Phase 2 results in refractory chronic cough in the fourth quarter of this year, and the Phase 2 results in pruritus associated with psoriasis by late 2018 or early 2019." ANALYST REACTION: On Monday, Jefferies analyst David Steinberg downgraded Menlo Therapeutics to Hold and cut his price target for shares to $20 from $41. The analyst said he is surprised that the Phase 2 clinical trial of serlopitant did not meet its primary or key secondary efficacy endpoints and has removed all revenue linked with the atopic dermatitis indication from his model. Steinberg continues to project successful outcomes for serlopitant's other ongoing development programs and looks forward to the key clinical data readouts in coming months, including Ph2 chronic cough data in the fourth quarter and Phase 2 pruritus associated with psoriasis data in late 2018/early 2019. Meanwhile, Piper Jaffray analyst David Amsellem called the miss of primary and secondary endpoints in the Phase IIb study a "big disappointment." The analyst, however, does not infer that the setback in atopic dermatitis "necessarily raises the risk" surrounding the prurigo nodularis Phase III trials. Prurigo nodularis is an altogether different condition, Amsellem told investors. He believes the trial miss "should not call into question the overall viability of serlopitant as an anti-pruritic agent." Amsellem reiterated an Overweight rating and $48 price target on Menlo Therapeutics. PRICE ACTION: Shares of Menlo Therapeutics have lost more than half their value on Monday morning, declining 71.3% to $10.09 in morning trading.

MNLO Menlo Therapeutics
$35.22

-1 (-2.76%)

02/20/18
JMPS
02/20/18
INITIATION
Target $44
JMPS
Outperform
Menlo Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis started Menlo Therapeutics with an Outperform rating and $44 price target, nothing that he forecasts launches of treatments of prurigo nodularis, psoriasis and atopic dermatitis in early 2022. Ellis believes the U.S. pruritus market could easily exceed $1B, he tells investors.
02/20/18
02/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Imax (IMAX) assumed with an Overweight at JPMorgan. 2. Gates Industrial (GTES) was initiated with an Outperform at RBC Capital and Credit Suisse, an Overweight at Morgan Stanley and KeyBanc, as well as a Buy at SunTrust, UBS, and Citi. 3. Menlo Therapeutics (MNLO) was initiated with an Outperform at JMP Securities, an Overweight at Piper Jaffray, and a Buy at Jefferies. 4. PlayAGS (AGS) was initiated with a Buy at SunTrust, BofA/Merrill, and Deutsche Bank. 5. PagSeguro Digital (PAGS) was initiated with a Neutral at JPMorgan, BofA/Merrill, UBS, and Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/09/18
JEFF
04/09/18
DOWNGRADE
Target $20
JEFF
Hold
Menlo Therapeutics downgraded to Hold from Buy at Jefferies
Jefferies analyst David Steinberg downgraded Menlo Therapeutics to Hold and cut his price target for the shares to $20 from $41. The analyst is surprised that the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis did not meet its primary or key secondary efficacy endpoints.
04/09/18
PIPR
04/09/18
NO CHANGE
Target $48
PIPR
Overweight
Piper reiterates Overweight on Menlo Therapeutics after Phase II miss
Piper Jaffray analyst David Amsellem calls Menlo Therapeutics' serlopitant missing the primary and secondary endpoints in a Phase IIb study in patients with pruritis associated with atopic dermatitis as "big disappointment." The analyst, however, does not infer that the setback in atopic dermatitis "necessarily raises the risk" surrounding the prurigo nodularis Phase III trials. Prurigo nodularis is an altogether different condition, Amsellem tells investors in a research note. He believes last night's trial miss "should not call into question the overall viability of serlopitant as an anti-pruritic agent." Amsellem reiterates an Overweight rating on Menlo Therapeutics.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

08:13
11/20/18
11/20
08:13
11/20/18
08:13
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRM

Iron Mountain

$33.46

-0.38 (-1.12%)

08:11
11/20/18
11/20
08:11
11/20/18
08:11
Initiation
Iron Mountain initiated  »

Iron Mountain initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOWR

Tower International

$29.99

0.51 (1.73%)

08:11
11/20/18
11/20
08:11
11/20/18
08:11
Hot Stocks
Breaking Hot Stocks news story on Tower International »

Tower International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$16.51

-0.23 (-1.37%)

08:10
11/20/18
11/20
08:10
11/20/18
08:10
Hot Stocks
Clovis issued second U.S. patent covering rucaparib »

Clovis Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BE

Bloom Energy

$14.50

-1.54 (-9.60%)

08:10
11/20/18
11/20
08:10
11/20/18
08:10
Conference/Events
Bloom Energy has a conference call hosted by JPMorgan »

JPMorgan Analyst Coster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

PME

Pingtan Marine Enterprise

$2.35

-0.05 (-2.08%)

08:09
11/20/18
11/20
08:09
11/20/18
08:09
Hot Stocks
Pingtan Marine Enterprise announces three new vessels sailed to sea »

Pingtan Marine Enterprise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRD

Nemaura Medical

$1.87

0.01 (0.54%)

08:09
11/20/18
11/20
08:09
11/20/18
08:09
Hot Stocks
Nemaura Medical signs exclusive license agreement with Al Danah Medical »

Nemaura Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

EQBK

Equity Bancshares

$37.02

-0.7 (-1.86%)

08:08
11/20/18
11/20
08:08
11/20/18
08:08
Initiation
Equity Bancshares initiated  »

Equity Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ESND

Essendant

$12.68

-0.02 (-0.16%)

08:08
11/20/18
11/20
08:08
11/20/18
08:08
Hot Stocks
Staples' affiliates extends expiration of tender offer for Essendant's shares »

Staples announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$7.84

-0.2 (-2.49%)

, BHGE

Baker Hughes

$23.00

-0.38 (-1.63%)

08:07
11/20/18
11/20
08:07
11/20/18
08:07
Recommendations
General Electric, Baker Hughes analyst commentary  »

GE 'fire sale'…

GE

General Electric

$7.84

-0.2 (-2.49%)

BHGE

Baker Hughes

$23.00

-0.38 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

HJLI

Hancock Jaffe Laboratories

$2.02

(0.00%)

08:07
11/20/18
11/20
08:07
11/20/18
08:07
Hot Stocks
Hancock Jaffe Laboratories receives update on VenoValve application from INVIMA »

Hancock Jaffe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

MTEM

Molecular Templates

$4.59

-0.17 (-3.57%)

08:06
11/20/18
11/20
08:06
11/20/18
08:06
Initiation
Molecular Templates initiated  »

Molecular Templates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADI

Analog Devices

$85.55

-3.94 (-4.40%)

08:06
11/20/18
11/20
08:06
11/20/18
08:06
Earnings
Analog Devices sees Q1 adjusted EPS $1.28, plus or minus 7c, consensus $1.35 »

Sees Q1 revenue $1.51B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

KLIC

Kulicke & Soffa

$19.90

-0.96 (-4.60%)

08:05
11/20/18
11/20
08:05
11/20/18
08:05
Initiation
Kulicke & Soffa initiated  »

Kulicke & Soffa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

08:05
11/20/18
11/20
08:05
11/20/18
08:05
General news
U.S. equities are getting de-FAANGed again »

U.S. equities are getting…

08:05
11/20/18
11/20
08:05
11/20/18
08:05
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

BWA

BorgWarner

$39.40

-0.345 (-0.87%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Conference/Events
BorgWarner management to meet with Wolfe Research »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

ADI

Analog Devices

$85.55

-3.94 (-4.40%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Earnings
Analog Devices reports Q4 adjusted EPS $1.55, consensus 1.52 »

Reports Q4 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

WOW

WideOpenWest

$10.02

-0.15 (-1.47%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Conference/Events
WideOpenWest management to meet with JMP Securities »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

  • 03

    Dec

TOWR

Tower International

$29.99

0.51 (1.73%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Hot Stocks
Tower International signs MOU to sell European operations »

Tower International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVFY

Nova Lifestyle

$0.87

-0.03 (-3.33%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Hot Stocks
Nova Lifestyle receives over $1M in orders from Barsala »

Nova LifeStyle announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXTR

Extreme Networks

$6.20

-0.25 (-3.88%)

, HPE

HP Enterprise

$14.83

-0.37 (-2.43%)

08:02
11/20/18
11/20
08:02
11/20/18
08:02
Hot Stocks
Extreme Networks appoints Remi Thomas as CFO »

Extreme Networks (EXTR)…

EXTR

Extreme Networks

$6.20

-0.25 (-3.88%)

HPE

HP Enterprise

$14.83

-0.37 (-2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

TGT

Target

$77.13

-1.9 (-2.40%)

08:02
11/20/18
11/20
08:02
11/20/18
08:02
Recommendations
Target analyst commentary  »

Target sales solid, buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

CBRL

Cracker Barrel

$174.86

5.18 (3.05%)

08:00
11/20/18
11/20
08:00
11/20/18
08:00
Downgrade
Cracker Barrel rating change  »

Cracker Barrel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

MSFT

Microsoft

$104.62

-3.66 (-3.38%)

08:00
11/20/18
11/20
08:00
11/20/18
08:00
Options
Microsoft put buyer realizes 25% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 28

    Nov

  • 04

    Dec

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.